This article was originally published in The Gray Sheet
Executive SummaryPlanned two-for-one stock split will be payable to shareholders of record on Dec. 28, the firm states. Certificates reflecting the spilt will be issued on or about Jan. 13, 1999. Approximately 31 mil. shares will be outstanding thereafter
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.